Passage Bio, Inc. (PASG) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Precision BioSciences, Inc.

ImmuCell Corp.

Marker Therapeutics, Inc.

VistaGen Therapeutics, Inc.

LAVA Therapeutics NV

Cognition Therapeutics, Inc.

Gain Therapeutics, Inc.

Passage Bio, Inc.

Quince Therapeutics, Inc.

Viracta Therapeutics, Inc.

CytoMed Therapeutics Ltd.

Why is Passage Bio, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Passage Bio, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Passage Bio, Inc.

-28.43%

0.26

1614.14%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

10.05%

EBIT to Interest (avg)

-117.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.28

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

71.40%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.09

EV to EBIT

0.52

EV to EBITDA

0.53

EV to Capital Employed

0.93

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

179.94%

ROE (Latest)

-209.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -30.65 MM

NET PROFIT(HY)

Higher at USD -17.67 MM

DEBT-EQUITY RATIO (HY)

Lowest at -234.69 %

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

EPS(Q)

Highest at USD -2.36

-3What is not working for the Company

ROCE(HY)

Lowest at -128.9%

CASH AND EQV(HY)

Lowest at USD 79.64 MM

Here's what is working for Passage Bio, Inc.

Operating Cash Flow

Highest at USD -30.65 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

Higher at USD -17.67 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -234.69 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

EPS

Highest at USD -2.36

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Passage Bio, Inc.

Cash and Eqv

Lowest at USD 79.64 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents